← Back to Clinical Trials
RecruitingNCT06560502

Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionDiabetic Foot Ulcer
SponsorStability Biologics
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment324
SexALL
Min Age21 Years
Max AgeN/A
Start Date2024-08-01
Completion2026-08
Interventions
Standard of Care-DFUAmnioCore - DFUAmnio Quad-Core - DFU

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a multicenter, prospective, randomized controlled modified multi-platform (matriarch) trial evaluating several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus standard of care alone in the management of nonhealing diabetic foot and venous leg ulcers.

Eligibility Criteria

Inclusion Criteria: * 1\. Subjects must be at least 21 years of age or older. 2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus. 3. At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 5.0 cm2 measured post debridement . 4\. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit. 5\. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus. 6\. The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. 7\. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable: a. ABI between 0.7 and ≤ 1.3; b. TBI ≥ 0.6; c. TCOM ≥ 40 mmH

Related Trials